Evotec
Sadman Sakib, PhD, is a Research Associate specializing in Molecular Biology and Next Generation Sequencing at Evotec since February 2022. Previous experience includes a postdoctoral position at the German Center for Neurodegenerative Diseases under Prof. Andre Fischer, where significant contributions were made in establishing research on long non-coding RNAs (lncRNAs) for RNA therapeutics, developing specialized FACS methods, and specializing in next-generation sequencing and bioinformatics. Sadman Sakib has also worked as a freelance science writer for EpiGentek and has completed several internships focused on neuroscience and molecular biology at institutions like the Max Planck Institute and Universitätsmedizin Göttingen. Educational qualifications include a PhD in Neuroscience from the International Max Planck Research School and a Master's Degree from the University of Bordeaux, complemented by a Bachelor’s Degree in Biochemistry and Molecular Biology from the University of Dhaka.
This person is not in the org chart
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.